: Gerhard Moser Investment Press Team/ Posted May 31, 2019 :

uniQure to Participate in Multiple Upcoming Industry Conferences

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in June:


Conference Listing

  • Gordon Research Conference: CAG Triplet Repeat Disorders, June 2 – 7, Lucca (Barga), Italy.

    • Joseph Higgins, M.D., F.A.A.N., VP, clinical development, Huntington’s disease program lead, will be presenting "Silencing CAG Repeats in Huntington’s Disease and SCA3" on Friday, June 7th at 6:05 p.m. CET.
    • In addition, uniQure will be presenting in the poster session on Wednesday June 5th and Thursday June 6th: “A novel AAV-based miQURE gene therapy for SCA3” (Poster #56).
  • European Reference Network – Rare Neurological Diseases (ERN-RND) Annual Meeting, June 17 – 19, Siena, Italy.
    • Astrid Valles-Sanchez, senior scientist biomarker research at uniQure, will be presenting “Developing microRNA-based gene therapies for Huntington Disease and Spinocerebellar Ataxia type 3” on Monday, June 17th at 3:40 p.m. CET.
  • Huntington’s Disease Society of America (HDSA) 34th Annual Convention, June 27 – 29, Boston, MA.
    • uniQure is a sponsor of the conference and will be presenting in the Boston Biotech HD Showcase session on Saturday, June 29 from 2:45 to 3:35 p.m. ET.

Gerhard Moser - We are huge advocates of UniQure and our specialist have been excited about thier 2018 financials which could possibly be showing a successful 2019.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. Find out more about uniQure

Find out company information on UniQure buy viewing thier Bloomberg Listing

process diagram image

Key Considerations

  • Initial risk assessment
  • Identifying your goals and aspirations
  • Growth, income and protection make top optimized portfolios
  • Most cost effective solutions all round

Our Added Value

  • Fully qualified advisers
  • Bespoke portfolio optimization system
  • Private banking fund platform
  • Non-market correlated funds

Speak to an Advisor Now?

Request a Callback!